

## Annexure A

Statement of Deviation or Variation for the quarter ended 30<sup>th</sup> September, 2021

Statement of Deviation / Variation in utilisation of funds raised	
Name of listed entity	Marksans Pharma Limited
Mode of Fund Raising	Preferential Issue
Date of Raising Funds	20.07.2021
Amount Raised	Rs. 93,09,99,994
Report filed for quarter ended	30 <sup>th</sup> September, 2021
Monitoring Agency	Not Applicable
Monitoring Agency Name, if applicable	Not Applicable
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not Applicable
If Yes, Date of shareholder Approval	Not Applicable
Explanation for the Deviation / Variation	Not Applicable
Comments of the Audit Committee after review	Nil
Comments of the auditors, if any	Nil

## Objects for which funds have been raised and where there has been a deviation, in the following table

Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds utilised till 30 <sup>th</sup> September, 2021	Amount of deviation/variation for the quarter according to applicable object	Remarks if any
The proceeds of the preferential issue are proposed to be used to strengthen the capital base and to enhance long term financial resources of the Company in order to fund expansion program of the Company.	None	Rs. 93,09,99,994	None	Rs. 93,09,90,041	Nil	No deviations



*Lawyer's*

**Deviation or variation could mean:**

- (a) **Deviation in the objects or purposes for which the funds have been raised or**
- (b) **Deviation in the amount of funds actually utilized as against what was originally disclosed or**
- (c) **Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc**

**For Marksans Pharma Limited**

*Harshavardhan Panigrahi*



Harshavardhan Panigrahi  
Company Secretary & Compliance Officer